IN VITRO PHARMACODYNAMIC EFFECTS OF CANGRELOR ON PLATELET P2Y12 RECEPTOR MEDIATED SIGNALING IN TICAGRELOR TREATED PATIENTS

Variability in the onset of platelet inhibitory effects induced by oral P2Y12 receptor antagonists, including ticagrelor, has been shown in high-risk settings. These findings underscore the need for intravenous P2Y12 inhibiting therapies, such as cangrelor, with immediate effects. However, to date